Clinical trials
Breast Cancer Patients clinical trials
Below are recruiting breast cancer patients clinical trials, each written for real people, not researchers. We’re tracking 2,247 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06832202RecruitingPhase 2
HLX22 plus Enhertu for HR+, HER2-low breast cancer
This trial tests a new drug, HLX22, combined with Enhertu (trastuzumab deruxtecan) for people with advanced breast cancer that is hormone receptor positive and HER2-low. The goal is to see if the combination works better than Enhertu alone.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06102824RecruitingPhase 2
Organoid-guided treatment for advanced breast cancer
This trial tests whether using a miniature version of your tumor grown in a lab can help choose the best treatment for advanced breast cancer. It compares this personalized approach to standard care.
Guangzhou, GuangdongAges 18–80 - NCT06839547Recruiting
Testing a new drug with radiation for advanced breast cancer brain tumors
This study looks at how well a new anti-tumor drug works when given along with radiation therapy for people whose advanced breast cancer has spread to the brain. It may help the radiation work better and control the cancer longer.
BeijingAges 18 years+ - NCT07284836RecruitingPhase 2
Chemo directly to liver for breast cancer
This trial tests a new way to give chemotherapy directly to the liver for breast cancer that has spread only there. It's for people who have already tried two or more standard treatments.
Hangzhou, ZhejiangAges 18–70 - NCT06860529RecruitingPhase 2
Immunotherapy plus chemo for early-stage HR+/HER2- breast cancer
This trial tests adding the immunotherapy drug serplulimab to standard chemotherapy for people with early-stage HR-positive, HER2-negative breast cancer. It aims to see if this combination can improve outcomes before surgery.
Zhengzhou, HenanAges 18 years+ - NCT06718933RecruitingPhase 1/Phase 2
Study of a drug combination for breast cancer that spread to the brain
This trial tests whether a combination of three drugs (SHR-A1811, pyrotinib, and bevacizumab) can help people with advanced breast cancer that has spread to the brain. It aims to shrink brain tumors and stop them from growing.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05759546RecruitingPhase 2
Test a PARP and CDK4/6 medicine plus hormone therapy
This Phase 2 study tests whether combining a PARP inhibitor with a CDK4/6 inhibitor and hormone (endocrine) therapy can help people with advanced HR-positive, HER2-negative breast cancer. It’s for certain patients who have not yet had chemotherapy or targeted therapy for metastatic disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05812807RecruitingPhase 3
Pembrolizumab versus monitoring after triple-negative breast cancer response
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Birmingham, AlabamaAges 18 years+ - NCT06876610Recruiting
Blood test for early breast cancer detection
This trial tests a blood test that looks for chemical changes in DNA to help diagnose breast cancer. It may offer a simpler way to detect cancer without needing a tissue sample.
Beijing, Beijing MunicipalityAges 30–75 - NCT06934239RecruitingPhase 4
AI-assisted vs. standard mammograms for breast cancer screening
This trial compares standard mammograms with mammograms aided by artificial intelligence (AI) to see if AI helps find breast cancer more accurately and reduces unnecessary callbacks. If you're 18 or older and getting a routine screening mammogram at one of the six participating health systems, you may be eligible.
Los Angeles, CaliforniaAges 18 years+ - NCT07407920RecruitingPhase 2
Optimizing treatment for early HER2+ and triple-negative breast cancer
This trial aims to see if patients who had a complete response to chemo before surgery can safely stop or reduce their targeted therapy afterward. It includes people with early-stage HER2-positive or triple-negative breast cancer who had no cancer cells left in the tissue removed at surgery (a pathological complete response).
Houston, TexasAges 18 years+ - NCT06917313RecruitingPhase 2
Fezolinetant for hot flashes in women with breast cancer on hormone therapy
This trial tests a drug called fezolinetant to see if it reduces hot flashes in women with HR+ breast cancer who are on hormone therapy (like tamoxifen or aromatase inhibitors). You need to be postmenopausal and having at least 7 moderate to severe hot flashes a day.
New Haven, ConnecticutAges 18 years+ - NCT06876714RecruitingPhase 3
Shorter vs Longer HER2 Therapy for Breast Cancer with Complete Response
This trial compares 6 months versus 12 months of HER2-targeted therapy for people with HER2+ breast cancer who had a complete response after chemo and trastuzumab. The goal is to see if a shorter treatment is just as effective.
Phoenix, ArizonaAges 18 years+ - NCT06890221Recruiting
Nutrition therapy before and after breast cancer surgery
This trial tests if a special nutrition drink before and after mastectomy can help breast cancer patients recover better. It uses a body measurement called bioimpedance phase angle to see how nutrition affects your cells and healing.
Petaling Jaya, Kuala LumpurAges 18 years+ - NCT06531135Enrolling by invitation
Counseling to help you adjust to breast cancer
This trial tests a counseling program to help people with breast cancer feel more positive and cope better. It's designed for newly diagnosed patients who can read and write Chinese.
TaipeiAges 20–70 - NCT06776861Recruiting
Radiation plus immunotherapy for advanced breast cancer
This study looks at combining radiation therapy with immunotherapy for advanced breast cancer that has spread or cannot be surgically removed. The goal is to see if adding radiation after treatment helps improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06734533Recruiting
Anlotinib combo for HR+ breast cancer that has spread
This trial tests a combination treatment including anlotinib for women with hormone receptor-positive breast cancer that has spread to other parts of the body and has stopped responding to standard therapies. It is for those who have already tried a CDK4/6 inhibitor and endocrine therapy.
Changsha, HunanAges 18–75 - NCT06679387RecruitingPhase 2
Memantine to prevent paclitaxel nerve damage in breast cancer
This trial tests whether the drug memantine can help prevent or reduce nerve pain and other side effects caused by the chemotherapy drug paclitaxel in breast cancer patients. If you are about to start weekly paclitaxel, this study may offer extra protection to your nerves.
CairoAges 18 years+ - NCT06616987RecruitingPhase 2
Preventing neutropenia from sacituzumab govitecan in TNBC
This trial tests whether a drug called sacituzumab govitecan can help prevent a low white blood cell count (neutropenia) in people with metastatic triple-negative breast cancer. It is for patients who have already received some chemotherapy but need a new treatment option.
SeoulAges 19 years+ - NCT06611891RecruitingPhase 3
PET scan study for breast cancer with hormone receptors
This study tests a special PET scan called 68Ga-DOTATOC to see if it can find certain breast cancer cells in the body. It may help doctors better understand your cancer, especially if it has spread to the liver or bones.
GrenobleAges 18–99 - NCT06686459Recruiting
AI-assisted single-session radiotherapy after breast-conserving surgery
This trial tests a new approach where all radiation is given in one session using AI guidance. It is for women who had breast-conserving surgery with lymph node removal and need radiation afterward.
GuangzhouAges 18–70 - NCT06518837RecruitingPhase 2
Tirzepatide for weight loss in early breast cancer
This study tests if tirzepatide (a weight loss drug) can help women and men with early-stage hormone receptor-positive breast cancer who are overweight or obese. The goal is to see if losing weight can improve outcomes after completing their initial breast cancer treatment.
Elizabeth, New JerseyAges 18 years+ - NCT07460752RecruitingPhase 2
Alternative injection site for goserelin in breast cancer patients
This trial is testing whether giving the drug goserelin in a different spot on the body works just as well for suppressing ovarian function in premenopausal women with hormone receptor positive breast cancer. You may be a fit if you've already been on goserelin shots in your abdomen for at least 6 months.
Rochester, MinnesotaAges 18–50 - NCT06382948RecruitingPhase 3
Elacestrant and everolimus for ESR1-mutant advanced breast cancer
This trial tests a new combination of two oral targeted therapy pills (elacestrant and everolimus) for people with a specific type of advanced breast cancer. It is for those whose cancer has an ESR1 mutation and has stopped responding to CDK4/6 inhibitors and hormone therapy.
InnsbruckAges 18 years+
Hear when a new Breast Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer patients?
- Yes. Clin2 currently lists 2,247 recruiting breast cancer patients studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer patients trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer patients trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.